Onglyza licence extended for use in combination with insulin

Onglyza (saxagliptin) can now be prescribed in combination with insulin for adults with type 2 diabetes, with or without metformin, when diet and exercise plus insulin alone do not provide adequate glycaemic control.

In a randomised, double-blind, placebo-controlled study (n=455), saxagliptin added to insulin therapy (with or without metformin) in patients with inadequate glycaemic control significantly reduced HbA1c and postprandial glucose levels compared with placebo at week 24. In an extension of the initial study, saxagliptin maintained the reduction in HbA1c levels at week 52 compared with placebo.

View Onglyza drug record

Further information: BMS/AstraZeneca

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New guidance for minimising psychological impact of COVID-19 pandemic in primary care patients
Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

MIMS launches Respiratory and Allergy Learning webinars

MIMS launches Respiratory and Allergy Learning webinars

Join us for the 2020 Respiratory and Allergy Learning...